Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 684 clinical trials

S Si-Yang Liu

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed …

18 years and older All Phase N/A
D Di Dong, Ph.D.

Classification of Benign and Malignant Lung Nodules Based on CT Raw Data

The employ of medical images combined with deep neural networks to assist in clinical diagnosis, therapeutic effect, and prognosis prediction is nowadays a hotspot. However, all the existing methods are designed based on the reconstructed medical images rather than the lossless raw data. Considering that medical images are intended for …

18 years and older All Phase N/A
C Charalampos Pierrakos, MD

Lung Ultrasound in COVID-19 Patients

To assess the prognostic performance of an early global LUS score with respect to the mortality in ICU and duration of ventilation.

18 years and older All Phase N/A
T Thierry Berghmans, MD, PhD

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

18 years and older All Phase N/A
C Charles TACQUARD, MD

Thromboembolic Events in Severe COVID-19 Patients

The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive …

18 years and older All Phase N/A
U Ulrich Matt, MD, PhD

Sequelae of Sars-CoV-2 Infections

By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the …

18 years and older All Phase N/A
D Danilo C Berton, Dr

Lung Function Exercise Capacity and Health-Related Quality of Life After Severe COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe disease requiring hospitalization and oxygen support in around14% of the cases and 5% require admission in intensive care unit. The medium and long-term impact in survivors of severe COVID-19 …

100 years and younger All Phase N/A
K Ke-Cheng Chen, M.D., Ph.D.

Evaluation of the Cell Detachment Ratio on pH-responsive Chitosan as a Prognostic Factor in Lung Cancer

Biomaterial-based cell culture models have been gaining increasing attention as potential therapeutic strategies. The purpose of this project is to evaluate whether the cell detachment ratio on pH-responsive chitosan could be correlated with the overall survival in lung cancer patients. Through controllable cell-material interaction, this project has the intention to …

20-70 years All Phase N/A
D Daniel M Beswick, MD

Impact of Sinus Surgery on Individuals With Cystic Fibrosis

This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of …

18-99 years All Phase N/A
P Paul LEGENDRE, MD

MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis

To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of systemic sclerosis.

18 years and older All Phase N/A

Simplify language using AI